# US 2019/0314348 A1 · Compounds and compositions for inducing chondrogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314348 A1
- Document ID: US20190314348A1
- Status: Published application
- Kind: A1
- Application number: 16/448,547
- Filed: 2019-06-21
- Published: 2019-10-17
- Earliest claimed: 2014-05-13
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Ha-Soon Choi; James Paul Lajiness; Srinivasa Reddy Natala; Bao Nguyen; Hank Michael James Petrassi; Zhicheng Wang
- Web page: https://patentgrep.com/patent/US20190314348A1

## CPC

- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/351: not condensed with another ring
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4245: Oxadiazoles
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 491/18: Bridged systems
- C07D 493/08: Bridged systems
- C12N 5/0655: {Chondrocytes; Cartilage}
- A61L 2300/412: Tissue-regenerating or healing or proliferative agents
- A61L 2430/06: for cartilage reconstruction, e.g. meniscus
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/1346: from mesenchymal stem cells
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.

## Claims

### Claim 1

A compound of Formula IB1:
or a pharmaceutically acceptable salt, or a stereoisomer thereof, wherein
R1 is a 5 or 6 membered heteroaryl, unsubstituted or substituted by 1 to 2 substituents independently selected from halo, C1-4alkyl, C1-4haloalkyl, and NHR14b, wherein R14b is hydrogen or C1-4alkyl; and
R3 is phenyl substituted by 1 to 2 substituents independently selected from halo, cyano, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, C1-6haloalkoxy, and phenyl, —C(O)R16, —C(O)OR16, wherein R16 is C1-6alkyl, and the phenyl substituent of R3 is unsubstituted or further substituted by 1 to 2 substituents independently selected from halo and cyano.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula IB1a′:
or a pharmaceutically acceptable salt, or a stereoisomer thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula IB1a″:
or a pharmaceutically acceptable salt, or a stereoisomer thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula IB1b′:
or a pharmaceutically acceptable salt, or a stereoisomer thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula IB1b″:
or a pharmaceutically acceptable salt, or a stereoisomer thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula IB1c′:
or a pharmaceutically acceptable salt, or a stereoisomer thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula 1B1c″:
or a pharmaceutically acceptable salt, or a stereoisomer thereof.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula 1B1d′:
or a pharmaceutically acceptable salt, or a stereoisomer thereof.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein the compound is of Formula 1B1d″:
or a pharmaceutically acceptable salt, or a stereoisomer thereof.

### Claim 10 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from pyrazolyl, oxadiazolyl, pyridinyl, pyrimidinyl and pyrazinyl, wherein the pyrazolyl, pyridinyl, pyrimidinyl or pyrazinyl is unsubstituted or substituted by —NH2, or trifluoromethyl.

### Claim 11 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from
wherein “*” represents the point of attachment of R1 to the bicyclic core ring.

### Claim 12 (depends on 1)

The compound according to claim 1 or a pharmaceutically acceptable salt, or a stereoisomer thereof, wherein R3 is selected from
wherein “*” represents the point of attachment of R3 to NH.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 1 or a pharmaceutically salt or stereoisomer thereof, and a pharmaceutically acceptable excipient.

### Claim 14 (depends on 13)

The composition according to claim 13, further comprising an agent selected from angiopoietin-like 3 protein (ANGPTL3), oral salmon calcitonin, SD-6010, vitamin D3, collagen hydrolyzate, FGF18, BMP7, rusalatide acetate, avocado soy unsaponifiables, a steroid, and a non-steroidal anti-inflammatory agent (NSAID) and hyaluronic acid.

### Claim 15 (depends on 1)

A method of treating osteoarthritis or rheumatoid arthritis in a mammal in need thereof, comprising administering a therapeutically effective amount of the compound of claim 1, and optionally in combination with a second agent, to a joint of the mammal.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said second agent is selected from hyaluronic acid, angiopoietin-like 3 protein (ANGPTL3), a growth factor, a chondrogenic agent, vitamin D3, collagen hydrolyzate, rusalatide acetate, avocado soy unsaponifiables (ASU), a steroid, and a non-steroidal anti-inflammatory agent (NSAID).

### Claim 17 (depends on 1)

A method for cartilage repair, comprising administering to a subject a therapeutically effective amount of a compound of a compound according to claim 1, and optionally in combination with a second agent; thereby repairing cartilage.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said second agent is selected from hyaluronic acid, angiopoietin-like 3 protein (ANGPTL3), a growth factor, a chondrogenic agent, vitamin D3, collagen hydrolyzate, rusalatide acetate, avocado soy unsaponifiables (ASU), a steroid, and a non-steroidal anti-inflammatory agent (NSAID).

### Claim 19 (depends on 1)

A method of inducing differentiation of mesenchymal stem cells into chondrocytes, comprising contacting mesenchymal stem cells with a compound according to claim 1, and optionally in combination with a second agent; thereby inducing differentiation of the stem cells into chondrocytes.

### Claim 20 (depends on 19)

The method according to claim 19, wherein said second agent is selected from hyaluronic acid, angiopoietin-like 3 protein (ANGPTL3), a growth factor, a chondrogenic agent, vitamin D3, collagen hydrolyzate, rusalatide acetate, avocado soy unsaponifiables (ASU), a steroid, and a non-steroidal anti-inflammatory agent (NSAID).
